Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Integrated Clinical and Epidemiological Research Ethical Guidelines to Take Effect April: MHLW
December 25, 2014
- Deliberations on Specific Cases of Cost-Effective Assessments to Be Closed to the Public: Chuikyo
December 25, 2014
- Investigation Finds No Intentional Data Falsification from J-ADNI Study
December 25, 2014
- MHLW Orders Revision of Package Insert for Jevtana
December 24, 2014
- Novartis Pharma Should Take Thorough Measures to Prevent Worker Involvement in IITs: Health Minister
December 22, 2014
- New “Compassionate Use” System to Be Introduced in FY2015; Will Apply to Industry-Sponsored Trials as well as IITs
December 22, 2014
- Orphan Designation to Be Expanded to Include Intractable Diseases Affecting More than 50,000 Patients
December 22, 2014
- MHLW OKs New Indication for Nesp, Pediatric Dosages for Cancidas
December 19, 2014
- LDP to Begin Intensive Tax Debate from December 25
December 19, 2014
- MHLW Releases Discussion Outline of ICH Lisbon Meeting
December 18, 2014
- LDP Tax Panel Execs Eye Slight Cut of R&D Tax Deduction Cap
December 17, 2014
- Drug Makers Present Cases in Which PI Trials in Japanese Could Be Omitted in Multinational Studies: PMDA Workshop
December 17, 2014
- Japan Tax Reform Plan Will Be Compiled by Year-End: Abe
December 16, 2014
- Editor’s Pick: Five Healthcare News Headlines for Dec. 1 - 14
December 15, 2014
- JPMA Will Work to Secure Quality, Transparency of Clinical Research for Purpose of Advertising: Vice President
December 15, 2014
- LDP Healthcare Big Names Cruise to Victory in Lower House Poll
December 15, 2014
- Panel Reveals Final Report Calling for Legal Regulations for Clinical Research
December 12, 2014
- Outline of New Global Clinical Trial Guidelines Agreed On at ICH Confab in Lisbon
December 12, 2014
- Elplat, Elaspol Generics to Join NHI Price List on Dec. 12
December 11, 2014
- Wholesalers’ Negative Primary Margin on Sales Widens Slightly in First Half of FY2014: Ryukaikon
December 11, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…